NCT03998748

Electrophysiological Correlates of Cognition in Depression

Terminated NA Last updated 19 January 2023

What this trial tests

NA trial testing Sham Genetic Feedback in Major Depressive Disorder in 80 participants. Terminated before completion.

Timeline

8 October 2019

Primary endpoint
1 August 2021

1 August 2022

Quick facts

Lead sponsor	Mclean Hospital
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	double
Primary purpose	basic science
Enrollment	80
Start date	8 October 2019
Primary completion	1 August 2021
Estimated completion	1 August 2022
Sites	1 location across United States

Drugs / interventions tested

• Sham Genetic Feedback

Conditions studied

• Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

Mclean Hospital

Who can join

Adults 18 to 45, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Biogenetic messages about the etiology of mental illness (e.g., the "chemical imbalance theory" of depression) are increasing but the impact that these have on decision-making and motivation is not yet clear. This study will evaluate the impact of biogenetic feedback on cognitive control and default-mode network functioning, as well as motivation for different psychiatric treatment modalities. Participants with major depressive disorder (MDD) will be instructed that they are being tested for genetic susceptibility to depression and will be randomized to receive feedback that they either do or do not have a genetic predisposition to depression. Before and after receiving this feedback, brain activity will be assessed using high-density electroencephalogram (EEG). The investigators hypothesize that those exposed to the genetic feedback condition will evidence heightened ruminative default mode network activity and perceive medications to be more effective than psychotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Limited impacts of biogenetic messaging on neural correlates of cognitive control and beliefs about depression.
   Lamontagne SJ, Duda JM, Madarasmi S, Rogers VA, et al · · 2023 · PMID 36869258 · DOI 10.3758/s13415-023-01073-9